Imunon Q3 net loss $6.1M ($0.87/sh); PLACCINE NHP data shows similar protection to mRNA vaccine

Imunon, Inc.

2023-Q3 EPS reported -$3.42 revenue$375,000

Net loss of $6.1M ($0.87 per share) vs $5.4M ($0.94 per share) in Q3 2021; operating expenses rose 21% to $6.3M.
Cash and investments of $43.4M; expects cash runway into 2025.
Phase I/II OVATION 2 study with GEN-1 fully enrolled (110 patients); topline results expected H1 2024.
PLACCINE NHP study: viral clearance >90% in vaccinated vs controls; protection comparable to commercial mRNA vaccine.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Imunon, Inc. reported financial results for the three-month and nine-month periods ended September 30, 2022.

Period: the three-month and nine-month periods ended September 30, 2022
Result: reported results

Exact text from the filing

IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J. (November 14, 2022) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three-month and nine-month periods ended September 30, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031636

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.